If you got a question, look no further.
We post the most common questions
in our FAQ section.
Please fill in the form below to receive a Free Sample of the Report.
Summary"PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012” report provides an in-depth understanding of the key deals that took place in the region during the last decade. The type of deals covered in the report include Mergers & Acquisitions (M&A), Licensing and Collaboration & Partnerships.The report also provides understanding on the regional differences in the deal making activity to that of the global trends and key trends are outlined with insight on drivers such as regulatory policy, macro-economic and industry factors as well as market access challenges. Case studies including the top five deals in value among Mergers & Acquisition, Licensing and Collaboration & Partnerships are strategically analyzed to provide comprehensive understanding on areas such as structure and status of the deal vis a vis the overall corporate strategy.HighlightsKey Questions Answered- How are the main deal categories faring among top countries in the Latin America region over the past five years?- What are the primary reasons for increased activity in strategic deals by leading pharmaceutical companies in LATAM region?- What are the key trends, and strategies involved in M&As, licensing deals, and collaboration agreements entered into by leading pharmaceutical and healthcare companies in the Latin American region?- What strategies are the most successful companies pursuing to gain and maintain their market leading position?- Which are the key companies that are potential targets of acquisitions?Scope- Report provides in-depth understanding of the key pharmaceutical and healthcare deals that took place in the LATAM region during the past five years. Furthermore, key deals are discussed from a domestic and global point of view.
- Current regulatory framework in various markets in LATAM including recent and/or ongoing developments that are expected to impact or influencing the industry are discussed. In-depth commentary on four countries in the region are included.
- Highly Insightful analyses on the deal making terms, strategic implications and synergies of recent deals activity in the LATAM pharmaceutical industry.
- Collaboration & Acquisition Strategies: Exhaustive discussion on the strategic implications and synergies of recent M&A and partnering activities. Case Studies of five deals are included in each deal category.
- Expert Insights on the corporate strategies of various drug companies seeking a competitive advantage in the pharmaceutical market place.
- Five major regional companies are profiled providing an in-depth analysis on their individual deal making strategies.
- Number of Case Studies on top deal making activities shedding light on rationale and strategy. Potential targets for acquisitions in the region are also identified.Reasons to buy- Understand the primary drivers behind major deal initiatives in the LATAM region.
- Analyze the structure of the deals and gain insight on the various factors considered when structuring deal terms in strategic acquisitions, mergers, collaborations, and licensing.
- Identify rationale behind potential takeover targets and partners, thereby maximizing your opportunities for consolidation, investment, and strategic partnerships in the Asia Pacific region.
- Use this information as an independent source for your due diligence and transaction strategy.
1 Table of Contents1 Table of Contents 71.1 List of Tables 101.2 List of Figures 122 Introduction 142.1 Report Scope 142.1.1 Key Questions Answered 142.1.2 Key Benefits 152.1.3 Upcoming Related Reports 153 Historical Dealmaking Trends 163.1 Overview 163.2 Leading Deal Drivers 173.2.1 Dampening Global Pharmaceutical Markets 173.2.2 Intellectual Property Issues and Rising Competition 183.2.3 Universal Healthcare Access, Primary Healthcare, and Health Insurance 193.2.4 Increasing Consolidation 203.3 Overall Deals in Review 213.3.1 Review by Deal Type 214 Regional Country Profiles 284.1 Brazil 284.1.1 Overview 284.1.2 Top Deals by Value and Volume 294.1.3 Market Dynamics 314.2 Mexico 344.2.1 Overview 344.2.2 Top Deals by Value and Volume 354.2.3 Market Dynamics 374.3 Argentina 414.3.1 Overview 414.3.2 Top Deals by Value and Volume 424.3.3 Market Dynamics 444.4 Venezuela 484.4.1 Overview 484.4.2 Top Deals by Value and Volume 494.4.3 Market Dynamics 515 Mergers and Acquisitions 555.1 Overview 555.2 Case Studies 575.2.1 UnitedHealth Group Acquires Amil Participações 575.2.2 Hypermarcas Acquires Mantecorp Indústria Química e Farmacêutica 595.2.3 Hypermarcas Acquires Laboratório Neo Química 605.2.4 Acquisition of Lafrancol (Colombia) by Recalcine (Chile) 615.2.5 Sanofi Aventis Acquires Medley Indústria Farmacêutica 626 Licensing Agreements 646.1 Overview 646.2 Case Studies 666.2.1 FBM Indústria Farmacêutica (FBM Farma) Enters into Licensing Agreement with Ampio Pharmaceuticals 666.2.2 FAES Farma and Pfizer Expand Bilastine License Agreement 676.2.3 CEL-SCI Enters into Licensing Agreement with IDC-GP Pharm 686.2.4 Vanda Pharma Enters into Licensing Agreement with Biotoscana Farma 706.2.5 Oxford Nutrascience Enters into Licensing Agreement with Aché Laboratórios 717 Collaborations and Partnerships 737.1 Overview 737.2 Case Studies 757.2.1 Pfizer Enters into an Agreement with Laboratório Teuto Brasileiro 757.2.2 Avesthagen Forms a Joint Venture with Uxmal 777.2.3 Baxter International Enters into Agreement with Hemobras for Recombinant Factor VIII (rFVIII) Hemophilia Treatment 787.2.4 Cristalia, Biolab, Eurofarma, and Libbs Enter into Joint Venture for Biological Medicines 807.2.5 Aché , Uniao Química Farmacêutica, Hypermarcas, and EMS Laboratories Set Up a Joint Venture 818 Deal Strategy of Major LATAM Companies 838.1 Amil Participações S.A. 838.1.1 Recent Deals: M&As, Licensing, and Partnerships 838.1.2 Overall Deal Strategy 848.2 Hypermarcas 858.2.1 Recent Deals: M&As, Licensing, and Partnerships 858.2.2 Overall Deals Strategy 868.3 Grupo Casa Saba 878.3.1 Recent Deals: M&As, Licensing, and Partnerships 878.3.2 Overall Deals Strategy 878.4 Genomma Lab Internacional 888.4.1 Recent Deals: M&As, Licensing, and Partnerships 888.4.2 Overall Deals Strategy 888.5 CFR Pharmaceuticals 898.5.1 Recent Deals: M&As, Licensing, and Partnerships 898.5.2 Overall Deals Strategy 909 Future Outlook 919.1 Overview 919.2 Deal-Making Trends 919.2.1 Mergers and Acquisitions 919.2.2 Licensing and Partnership Deals to Rise in Quest for Portfolio and Pipeline Growth 939.2.3 Market Access Challenges will Impact Deal Activity 9310 Appendix 9510.1 Bibliography 9510.2 Abbreviations 9710.3 About the Author 10010.3.1 Industry Analyst 10010.4 Director of Healthcare Industry Dynamics 10010.5 Global Head of Healthcare 10110.6 About the Industry Dynamics Team 10110.7 About GlobalData 10110.8 Disclaimer 1021.1 List of TablesTable 1: Overview of Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Brazil, 2008-2012 29Table 2: Market Share Split of Pharma Firms in Brazil 33Table 3: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Mexico, 2008-2012 35Table 4: Pharmaceutical Market, Mexico, Forecast ($bn), 2011-2020 38Table 5: Top 10 Pharma Firms in Mexico Revenue-Wise 39Table 6: Top Healthcare Distribution Firms in Mexico Revenue-Wise 40Table 7: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Argentina, 2008-2012 42Table 8: Pharmaceutical Market, Argentina, Revenue ($bn), Forecast, 2013-2020 45Table 9: Top 10 Pharma Firms in Argentina, Revenue-Wise 46Table 10: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Venezuela, 2008-2012 49Table 11: Pharmaceutical Market ($bn), Venezuela, Forecast, 2012-2020 52Table 12: Top 10 M&A Deals by Value, LATAM Region, 2008-2012 56Table 13: UnitedHealth Acquires Amil Participações 57Table 14: Hypermarcas Acquires Mantecorp 59Table 15: Hypermarcas Acquires Laboratório Neo Química Comércio e Indústria 60Table 16: Recalcine Acquires Lafrancol 61Table 17: Sanofi Aventis Acquires Medley Indústria Farmacêutica 62Table 18: Major Licensing Deals, LATAM Region, 2008-2012 64Table 19: FBM Farma Indústria Farmacêutica Licenses Zertane from Ampio Pharmaceuticals 66Table 20: Pfizer and Faes Farma in Licensing Deal for Bilastine 67Table 21: CEL-SCI Enters into Licensing Agreement with IDC-GP Pharm 68Table 22: Vanda Pharma Enters into Licensing Agreement with Biotoscana Farma 70Table 23: Oxford Nutrascience Enters into Licensing Agreement with Ache Laboratórios 71Table 24: Top 10 Collaboration and Partnership Deals in the LATAM Region, 2008-2012 74Table 25: Pfizer Enters Into An Agreement With Laboratório Teuto Brasileiro 75Table 26: Avesthagen Enters into Agreement with Uxmal 77Table 27: Baxter International Enters Into Agreement With Hemobras 78Table 28: Cristalia, Biolab, Eurofarma and Libbs Enter into Joint Venture 80Table 29: Aché , Uniao Química Farmacêutica , Hypermarcas, and EMS Laboratories Set Up a Joint Venture 81Table 30: Amil Participações ’ Recent Deals Activity 83Table 31: Hypermarcas’ Recent Deals Activity 85Table 32: Grupo Casa Saba’s Recent Deals Activity 87Table 33: Genomma Lab Internacional’s Recent Deals Activity 88Table 34: CFR Pharmaceuticals’ Recent Deals Activity 891.2 List of FiguresFigure 1: Foreign Direct Investment Flow, LATAM Region, 2011-2012 17Figure 2: Research and Development Spending of PhRMA Members, 2005-2012 18Figure 3: Trend in M&A Deal Volume, LATAM Region, 2008-2012 22Figure 4: Trend in M&A Deal Values, LATAM Region, 2008-2012 23Figure 5: Volume of Licensing Deals, LATAM Region, 2008-2012 24Figure 6: Trend in Licensing Deal Values, LATAM Region, 2008-2012 25Figure 7: Trend in Collaboration and Partnership Deal Volumes, LATAM Region, 2009-2012 26Figure 8: Trend in Collaboration and Partnership Deal Values, LATAM Region, 2009-2012 27Figure 9: Trends in Deal Volume in Brazil, 2008-2012 30Figure 10: Volume of Deal Types in Brazil, 2008-2012 31Figure 11: Pharmaceutical Market, Brazil, Revenue ($bn), Forecast, 2013-2020 32Figure 12: Trends in Deal Volume in Mexico, 2008-2012 36Figure 13: Volume of Deal Types in Mexico, 2008-2012 37Figure 14: Trend in Market Forecast in Mexico, 2011-2020 38Figure 15: Trends in Deal Volume in Argentina, 2008-2012 43Figure 16: Volume of Deal Types in Argentina, 2008-2012 44Figure 17: Pharmaceutical Market, Argentina, Revenue ($bn), Forecast, 2013-2020 45Figure 18: Trends in Deal Volume in Venezuela, 2009-2012 50Figure 19: Trends in Volume of Deal Types in Venezuela, 2009-2012 50Figure 20: Pharmaceutical Market ($bn), Venezuela, Forecast, 2012-2020 52Figure 21: Number of M&A Deals in Major Countries, LATAM Region, 2008-2012 57Figure 22: Split in Volume of Licensing Deals among Drug Development Phases, LATAM Region, 2008-2012 65